Exploiting gene dependency to inform drug development for multiple myeloma

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Multiple myeloma (MM) remains an incurable cancer despite therapeutic advancements.
• Targeting tumor-specific essential genes presents a strategy to overcome drug resistance in MM.
• Identifying druggable dependencies is crucial for developing novel MM therapies.

Purpose of the Study:

• To identify essential genes in multiple myeloma (MM) using large-scale genetic perturbation data.
• To investigate the correlation between the expression of identified MM essential genes and patient outcomes.
• To explore the potential for repurposing existing drugs and developing new therapeutic agents for MM.

Main Methods:

• Analysis of DepMap project data to identify 23 essential genes in multiple myeloma.
• Examination of gene expression data in three independent patient cohorts (totaling 1503 cases).
• Statistical analysis to assess the association between gene expression and progression-free survival.

Main Results:

• The expression of TCF3 and FLVCR1 was significantly associated with progression-free survival in MM patients.
• IKBKB, an existing drug target, shows potential for MM repurposing.
• PIM2 is currently under investigation for MM treatment.

Conclusions:

• Large-scale genetic screens are valuable for identifying therapeutic targets in MM.
• TCF3 and FLVCR1 expression levels can serve as prognostic markers for MM.
• Targeting essential genes offers a promising avenue for overcoming MM drug resistance and improving patient outcomes.